Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/103507| Title: | Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab : two case reports |
| Authors: | Gamoudi, Donia Cutajar, Melanie Gamoudi, Nadia Camilleri, David James Gatt, Alexander |
| Keywords: | Anticoagulants (Medicine) Antiphospholipid syndrome Rituximab Thrombocytopenia Thrombosis |
| Issue Date: | 2017 |
| Publisher: | John Wiley & Sons Ltd. |
| Citation: | Gamoudi, D., Cutajar, M., Gamoudi, N., Camilleri, D. J., & Gatt, A. (2017). Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports. Clinical Case Reports, 5(6), 845. |
| Abstract: | In AP syndrome (APS) with severe thrombocytopenia, rituximab represents a unique drug which can balance the effect of bleeding and thrombosis. By reducing the production of autoantibodies, rituximab can simultaneously raise the platelets and reduce the chance of thrombosis by suppressing APL antibodies. Rituximab can supersede splenectomy as second-line therapy in similar patients. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/103507 |
| ISSN: | 20500904 |
| Appears in Collections: | Scholarly Works - FacM&SPat |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Achieving_a_satisfactory_clinical_and_biochemical_response_in_antiphospholipid_syndrome_and_severe_thrombocytopenia_with_rituximab_two_case_reports(2017).pdf | 174.74 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.